Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

PRESS RELEASES

19th May 2023

MAIDEN: A new global research consortium established to combat the rising burden of fatty liver disease

MAIDEN, the METABOLIC FATTY LIVER DISEASE CONSORTIUM is a medical, patient and stakeholder confederation that spans the Asia Pacific region and comprises 146 key opinion leaders from 22 countries/administrative regions (as per MAY 2022). As well as these Asia Pacific clinical experts, this ground-breaking consortium is engaging globally with stakeholders worldwide.

 

The consortium will address the rising global impact of Metabolic (dysfunction)-associated fatty liver disease (MAFLD) on human health by fostering research partnerships across low, middle, and high resource settings and across various health systems environments.

 

Professor Jacob George, Chair of the Consortium, WIMR and the University of Sydney stated, “The MAIDEN network provides a unique opportunity to advance multidisciplinary research to reduce the health, economic, and societal burden of MAFLD. I am absolutely delighted to be working with such extraordinary and expert group of colleagues, regional centres and institutes across the world in this endeavour”.

 

“The network’s research will focus on pursuing excellence in liver research, the clinical practice of fatty liver disease, and will provide education to all those interested in MAFLD”. “The consortium in its charter will uphold and embed an evidence-based scientific approach that we expect will be acceptable to the 5 P’s (Patients, Physicians, Pharma, Policy makers and the Public)”, Professor Mohammed Eslam, WIMR and the University of Sydney added.

 

“I encourage everyone to join us on this journey to promote MAFLD awareness and to contribute to our goals and aspirations – a world in which now no one suffers from the consequences of MAFLD” concluded, Professor George Lau, Humanity and Health Medical Group, HKSAR, China.

Further Information:

MAIDEN Media Relations

Email: press@maiden-apasl.com

Twitter: @MAIDEN_MAFLD

For any 1:1 interviews with one of the standing committee of MAIDEN please contact Communication Officer at MAIDEN. Email: info@maiden-apasl.com

Back to press releases page